In this episode, David Flores speaks with Matt Zemon, the co-founder of Happy and author of Psychedelic for Everyone. David and Matt open up about personal stories about their childhood, with Matt sharing a beautiful story about connecting with his son Cole.
In this interview, David Flores sits down with Dr. Mike…
Fireside Project is excited to launch on April 14th as a 24/7 support hotline
Kelsey Ramsden, the President, and CEO of Mind Cure Health Inc. sheds light on the advancements Mind Cure is currently making.
In this episode of the Psychedelic Spotlight podcast, we speak…
Michelle opens up about how her work as a cannabis writer led her down the path of psychedelics, her interest in safe magic mushroom use and why she was compelled to write her guidebook Your Psilocybin Mushroom Companion.
NEW MindMed MDMA trials, Compass Pathways Patent, Small Pharma DMT Trials Begins | MNMD, CMPS, DMT
What’s up psychedelic investors! We have been seeing a lot of red in the last few months. Companies like MindMed (MNMD: NASDAQ) (MMED:NEO), Compass Pathways (CMPS: NASDAQ) &Small Pharma ( OTC: DMTTF) ( CVE: DMT) have had huge news in the last week. So in this episode we’ll be covering the major news surrounding these psychedelic stocks!
Enjoy the episode!
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Music from:
www.bensound.com
Video editing: @themyaholy
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#MindMed #CompassPathways #PsychedelicStocks
By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.
